PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|June 2, 2015
Sharp Rise in Emergency Contraceptive Sales in Germany
Author(s)News Update
June 2, 2015.
Advertisement
Following the "morning after" pill's release from prescription requirement in Germany on March 14 this year, sales increased in April by more than 10 per cent to 55.000 packs, according to data from
Almost 100 percent of emergency contraceptives in Germany are sold by ellaOne and HRA-Pharma's PiDaNa. While the monthly sales quantity of ellaOne more than doubled during the last six months, PiDaNa shows a decrease of more than a third in its monthly sales quantity. This however is because PiDaNa's Levonorgestrel was not released from prescription requirement until after ellaOnes’ Ulipristal, reports INSIGHT.
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5